Table 1.
Baseline of patients included in this analysis
| Discovery dataset (n = 433) | External validation dataset (Shanghai + Xiamen, n = 568) | P value* | ||
|---|---|---|---|---|
| Nanning (n = 177) | Huai'an (n = 256) | |||
| Male (%, n) | 68.4% (121/177) | 79.7% (204/256) | 71.4% (411/576) a | NA |
| Age (years) (median, IQR) | 41.0 (34.0‐47.0) | 38.0 (29.0, 46.0) | 35.0 (28.0‐44.2) | NA |
| AST (U/L) (median, IQR) | 28.0 (22.0‐40.0) | 36.0 (26.0, 58.5) | 57.0 (37.0‐100.2) | NA |
| ALT (U/L) (median, IQR) | 34.0 (24.0‐47.0) | 42.0 (28.0, 79.8) | 99.0 (49.8‐204.2) | NA |
| PLT (109/L) (median, IQR) | 174.9 (149.0‐217.6) | 148.5 (110.5,190.5) | 166.5 (125.8‐201.2) | NA |
| APRI (median, IQR) | 0.5 (0.3‐1.0) | 1.0 (0.6‐1.9) | <.001 | |
| FIB‐4 (median, IQR) | 1.2 (0.8‐2.2) | 1.2 (0.8‐2.4) | .482 | |
| Fibrosis stage | ||||
| F0(%, n) | 15.0% (65) | 10.7% (61) | <.001 | |
| F1(%, n) | 19.9% (86) | 33.1% (188) | ||
| F2(%, n) | 16.6% (72) | 25.7% (146) | ||
| F3(%, n) | 23.3% (101) | 11.6% (66) | ||
| F4(%, n) | 25.2% (109) | 18.8% (107) | ||
NA, difference test could not be done, because raw data of some variables (including male, age, AST, ALT, PLT) from Huai'an dataset were not available.
Abbreviations: ALT, alanine aminotransferase; AST, aminotransferase; PLT, platelet count.
a
Eight patients with missing data in the validation cohort are deleted in the analysis except for sex ratios.
*
P value compare patients from discovery dataset against those from extern validation dataset (Wilcoxon rank‐sum test for continuous variables; Chi‐square test for categorical variables).